Legend Biotech (LEGN) Debt to Equity: 2020-2025
Historic Debt to Equity for Legend Biotech (LEGN) over the last 4 years, with Sep 2025 value amounting to $0.17.
- Legend Biotech's Debt to Equity fell 36.03% to $0.17 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.17, marking a year-over-year decrease of 36.03%. This contributed to the annual value of $0.29 for FY2024, which is 28.75% up from last year.
- According to the latest figures from Q3 2025, Legend Biotech's Debt to Equity is $0.17, which was down 43.26% from $0.30 recorded in Q2 2025.
- In the past 5 years, Legend Biotech's Debt to Equity registered a high of $0.41 during Q1 2023, and its lowest value of $0.07 during Q2 2021.
- Over the past 3 years, Legend Biotech's median Debt to Equity value was $0.25 (recorded in 2024), while the average stood at $0.26.
- Per our database at Business Quant, Legend Biotech's Debt to Equity soared by 2,416.41% in 2021 and then slumped by 39.56% in 2024.
- Quarterly analysis of 5 years shows Legend Biotech's Debt to Equity stood at $0.16 in 2021, then surged by 125.05% to $0.35 in 2022, then plummeted by 36.48% to $0.22 in 2023, then increased by 28.75% to $0.29 in 2024, then slumped by 36.03% to $0.17 in 2025.
- Its Debt to Equity stands at $0.17 for Q3 2025, versus $0.30 for Q2 2025 and $0.30 for Q1 2025.